Ropporin was identified as a potential target for immunotherapy in multiple myeloma, where its expression was detected in 44% of cases and its immunogenic potential was confirmed by the presence of antibodies and cytotoxic lymphocytes [31]. This evidence concerns the gene ROPN1 and plasma cell myeloma.